tiprankstipranks
Trending News
More News >
Vivoryon Therapeutics AG (NL:VVY)
:VVY
Advertisement

Vivoryon Therapeutics AG (VVY) Price & Analysis

Compare
0 Followers

VVY Stock Chart & Stats


Vivoryon Therapeutics AG News

VVY FAQ

What was Vivoryon Therapeutics AG’s price range in the past 12 months?
Vivoryon Therapeutics AG lowest stock price was €1.37 and its highest was €3.00 in the past 12 months.
    What is Vivoryon Therapeutics AG’s market cap?
    Vivoryon Therapeutics AG’s market cap is €43.74M.
      When is Vivoryon Therapeutics AG’s upcoming earnings report date?
      Vivoryon Therapeutics AG’s upcoming earnings report date is Oct 30, 2025 which is in 54 days.
        How were Vivoryon Therapeutics AG’s earnings last quarter?
        Vivoryon Therapeutics AG released its earnings results on Sep 04, 2025. The company reported -€0.21 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.21.
          Is Vivoryon Therapeutics AG overvalued?
          According to Wall Street analysts Vivoryon Therapeutics AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Vivoryon Therapeutics AG pay dividends?
            Vivoryon Therapeutics AG does not currently pay dividends.
            What is Vivoryon Therapeutics AG’s EPS estimate?
            Vivoryon Therapeutics AG’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Vivoryon Therapeutics AG have?
            Vivoryon Therapeutics AG has 26,066,809 shares outstanding.
              What happened to Vivoryon Therapeutics AG’s price movement after its last earnings report?
              Vivoryon Therapeutics AG reported an EPS of -€0.21 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.22%.
                Which hedge fund is a major shareholder of Vivoryon Therapeutics AG?
                Currently, no hedge funds are holding shares in NL:VVY

                Company Description

                Vivoryon Therapeutics AG

                Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.

                Vivoryon Therapeutics AG (VVY) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                Pharming Group
                Galapagos

                Ownership Overview

                0.53%99.47%
                Mutual Funds
                ― Other Institutional Investors
                99.47% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis